Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated promising
clinical activity in multiple cancers. However, resistance to PARP inhibitors remains a …

PKC comprises a large family of serine/threonine kinases that share a requirement for
allosteric activation by lipids. While PKC isoforms have significant homology, functional …

Background Anti-depressants have been reported to own anti-tumor potential types of
cancers; however, the role of imipramine in non-small cell lung cancer (NSCLC) has not …

Lung cancer remains a major health problem despite the considerable research into
prevention and treatment methods. Through a deeper understanding of tumors, patient …

Osimertinib (AZD9291) has been widely used for the treatment of EGFR mutant non-small
cell lung cancer. However, resistance to osimertinib is inevitable. In this study we elucidated …

Notch1 is a crucial oncogenic driver in T-cell acute lymphoblastic leukemia (T-ALL), making
it an attractive therapeutic target. However, the success of targeted therapy using γ …